Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: Using PRNT50 as an endpoint for immunogenicity

Vaccine

Volumn 28, Issue 12, 2010, Pages 2436-2441

  Reisler, Ronald B ^a   Danner, Denise K ^a   Gibbs, Paul H ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Japanese encephalitis; Japanese encephalitis vaccine; Plaque reduction neutralization test (PRNT)

Indexed keywords

INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG SCREENING; EPIDEMIC ENCEPHALITIS; FEMALE; HUMAN; IMMUNOGENICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; SERODIAGNOSIS; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS NEUTRALIZATION; VIRUS PLAQUE;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENCEPHALITIS, JAPANESE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TIME FACTORS; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 77249158334     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.080     Document Type: Article

References (19)

1. Halstead S.B., and Jacobson J. Japanese encephalitis vaccines. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. 5th ed. (2008), Elsevier, Philadelphia, PA 311-351
2. Petersen L.R., and Barrett A.D. Arthropod-borne flaviviruses. In: Richman D.D., Whitley R.J., and Hayden F.G. (Eds). Clinical virology. 3rd ed. (2009), ASM Press, Washington, DC 1173-1214
3. Benenson M.W., Top F.H., Gresso W., Ames C.W., and Alstatt L.B. The virulence to man of Japanese encephalitis virus in Thailand. Am J Trop Med Hyg 24 (1975) 974-980
4. CDC. Inactivated Japanese encephalitis virus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 42 RR-01 (1993) 1-16
5. WHO. Wkly Epidemiol Rec 80 (2005) 241-248. http://www.who.int/wer/2005/wer8028.pdf (accessed August 7, 2009)
6. Centers for Disease Control and Prevention. CDC health information for international travel 2010 (2009), U.S. Department of Health and Human Services, Public Health Service, Atlanta
7. Centers for Disease Control and Prevention. Japanese encephalitis among three U.S. travelers returning from Asia, 2003-2008. MMWR 58 (2009) 737-740
8. Mangiafico J.A., Sanchez J.L., Figueiredo L.T., LeDuc J.W., and Peters C.J. Isolation of a newly recognized Bunyawera serogroup virus from a febrile human in Panama. Am J Trop Med Hyg 39 (1988) 593-596
9. Hepburn M.J., Kortepeter M.G., Pittman P.R., Boudreau E.F., Mangiafico J.A., Buck P.A., et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24 (2006) 2843-2849
10. SAS Institute Incorporated, 2009. Cary, NC.
11. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomized controlled trial. Lancet 370 (2007) 1847-1853
12. Gambel J.M., DeFraites R., Hoke Jr. C., Brown A., Sanchez J., Karabatsos N., et al. Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series. JID 171 (1995) 1074
13. Defraites R.F., Gambel J.M., Hoke Jr. C.H., Sanchez J.L., Withers B.G., Karabatsos N., et al. Japanese encephalitis vaccine (inactivated, Biken) in US soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg 61 (1999) 288-293
14. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn 30 (1988) 175-184
15. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18 (2000) 26-32
16. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine 25 (2007) 5233-5243
17. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23 (2005) 5205-5211
18. Roehrig J.T., Hombach J., and Barrett A.D.T. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21 (2008) 123-132
19. Johnson A.J., and Roehrig J.T. New mouse model for dengue virus vaccine testing. J Virol 73 (1999) 783-786